Pfizer Sues To Delay Ranbaxy Lipitor Generic Another Six Years (India)
This article was originally published in PharmAsia News
Pfizer has filed two more patent suits against Ranbaxy Laboratories, this time in the United States, to extend protection of the anti-cholesterol Lipitor (atorvastatin calcium) patent until 2016. Ranbaxy's atorvastatin generic currently can be sold in the United States beginning in 2010. Pfizer contends those sales of the drug would infringe on its patent on Caduet, a combination of Lipitor and Norvasc (amlodipine besylate), by itself indicated for hypertension. Previous court wins by Ranbaxy allowed the firm to launch its Lipitor generic in 2010, a year ahead of expiration of Pfizer's patent on the drug.(Click here for more
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.